Firefly Inks Latest Commercial Agreement for Use of its FDA-Cleared BNA™ Platform in Groundbreaking Precision Neuroscience Research
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 14 2025
0mins
Should l Buy AIFF?
Source: Newsfilter
Collaboration on Genetic Research: Firefly Neuroscience is collaborating with Prof. Dr. Christian Schaaf from Heidelberg University Hospital on a study investigating the neurophysiological effects of 15q13.3 copy number variants (CNVs) using EEG technology, aiming to identify biomarkers and support diagnostic strategies for neurodevelopmental disorders.
Commercial Strategy and Technology Development: Firefly is focusing on building its licensing business as part of its commercial strategy, leveraging its FDA-cleared Brain Network Analytics technology to enhance brain health outcomes and attract pharmaceutical companies for drug research and clinical trials.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AIFF?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AIFF
About AIFF
Firefly Neuroscience, Inc. is an artificial intelligence (AI) technology company developing neuroscientific solutions to improve brain health outcomes for patients with mental illnesses and neurological disorders. The Company has developed its FDA-510(k) cleared Brain Network Analytics software platform (the BNA Platform) and is focused on advancing diagnostic and treatment approaches for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. The Company's Brain Network Analytics is a neurophysiological assessment tool that uses artificial intelligence and machine learning to analyze electroencephalogram (EEG) data recorded during rest and cognitive activity. The BNA Platform, in conjunction with an EEG system, provides clinicians with comprehensive insights into brain function (cognition).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Firefly Neuroscience Expands Commercial Footprint 20-Fold
- Commercial Footprint Expansion: Firefly Neuroscience reported a remarkable 20-fold expansion of its commercial footprint, with partnerships reaching 99 and over 10,800 EEG/ERP brain scans completed, indicating strong growth potential in the market.
- Clinical Assessment Surge: Year-over-year, partner sites increased by 1,880% and clinical assessments surged by 3,227%, showcasing the company's rapid development and significant market acceptance in brain scanning technologies.
- Database Growth: Firefly's proprietary database now contains over 191,000 EEG/ERP brain scans, making it the largest known standardized EEG/ERP repository, which lays a solid foundation for future research and commercial applications.
- Stock Performance: Despite a 63.40% decline in share price over the past 12 months, the stock is currently trading 103.6% above its 20-day simple moving average, indicating a strong short-term rebound; however, the RSI suggests overbought conditions, warranting caution for investors.
See More
GAD Therapies Market Expected to Reach $4.26B by 2033 Amid Rising Demand
- Market Growth Potential: The global market for Generalized Anxiety Disorder (GAD) treatments is projected to grow from $1.8 billion in 2023 to $4.26 billion by 2033, reflecting a robust annual growth rate of approximately 9%, driven by increasing awareness of mental health and demand for innovative solutions.
- Diverse Treatment Options: In addition to traditional anti-anxiety and antidepressant medications, the rise of cognitive-behavioral therapy and digital mental health tools has enhanced accessibility and effectiveness, allowing patients to manage symptoms in more flexible ways.
- Helus Pharma Drug Development: Helus Pharma announced positive topline results from its Phase 2 signal detection study for HLP004, indicating significant potential for this treatment to benefit adults with moderate-to-severe GAD who have not responded to existing therapies, thus offering new hope for underserved patients.
- Investment Outlook: As mental health care becomes increasingly integrated into mainstream healthcare systems, the broader anxiety treatment market is expected to exceed $12 billion in the next decade, with ongoing investments from companies and investors likely to drive long-term growth in this sector.
See More
GAD Therapies Market Expected to Reach $4.26B by 2033 Amid Rising Demand
- Market Growth Potential: The global market for generalized anxiety disorder (GAD) treatments is projected to grow from $1.8 billion in 2023 to $4.26 billion by 2033, reflecting a 9% annual growth rate driven by increasing awareness of mental health and demand for innovative solutions.
- Therapeutic Innovation: Helus Pharma's HLP004 demonstrated significant efficacy in a Phase 2 clinical trial for moderate-to-severe GAD patients, achieving an average reduction of 10.4 points in the Hamilton Anxiety Rating Scale (p<0.0001) within six weeks, offering new hope for patients who have not responded to existing treatments.
- Positive Patient Response: At six months, 67% of participants showed treatment response and 39% achieved remission, indicating that HLP004 provides durable effects and could potentially transform the treatment landscape for GAD.
- Optimistic Industry Outlook: The rise of digital mental health tools and telehealth has significantly improved treatment accessibility, and investments by Helus Pharma and other companies in mental health solutions are expected to drive continued market growth to meet the increasing patient demand.
See More
Firefly Neuroscience Shares Surge Amid Major Growth in EEG/ERP Scans
- Expanded Commercial Footprint: Firefly reported a remarkable 20-fold expansion of its commercial footprint and a 33-fold increase in EEG/ERP brain scan volumes, indicating strong growth potential in the market.
- Partnership Growth: By the end of 2025, Firefly established partnerships with 99 commercial users, completing over 10,800 EEG/ERP brain scans, reflecting year-over-year increases of 1,880% in partner sites and 3,227% in clinical assessments, showcasing its growing influence in the industry.
- Data Storage Advantage: Firefly's proprietary database now consists of over 191,000 EEG/ERP brain scans, making it the largest known standardized EEG/ERP repository, which will enhance its capabilities in AI-driven biomarker discovery.
- Technological Innovation Outlook: CEO Greg Lipschitz stated that with an exponentially growing foundation of clean data and NVIDIA L40S GPU acceleration, Firefly is poised to achieve new breakthroughs in cognitive brain biomarker discovery, advancing its goal of building the world's first EEG/ERP-based foundation model of the human brain.
See More
Firefly Neuroscience Reports Major Operational Surge
- Commercial Footprint Expansion: Firefly Neuroscience has achieved over a 20-fold increase in its commercial footprint over the past year, indicating a significant enhancement in market penetration that is expected to drive future revenue growth.
- EEG Scan Volume Surge: The company reported a 33-fold increase in EEG/ERP brain scan volumes, reaching over 10,800 scans, reflecting strong demand and market recognition in the neuroscience field, which may attract more investor interest.
- Partnership Network Growth: Firefly now partners with 99 commercial sites, aiming to complete over 10,800 brain scans by the end of 2025, a collaborative model that will enhance its market competitiveness and brand influence.
- Positive Market Reaction: Following the operational update, Firefly Neuroscience's stock surged over 45% in Wednesday's premarket trading, demonstrating strong market confidence in its growth potential and positive investor sentiment.
See More
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Firefly Neuroscience, Inc. (NASDAQ: AIFF)
Investigation Announcement: Purcell & Lefkowitz LLP is investigating Firefly Neuroscience, Inc. to determine if its directors breached fiduciary duties related to recent corporate actions.
Shareholder Rights: Shareholders of Firefly Neuroscience are encouraged to seek information about their rights and options through the law firm, which offers consultations at no cost.
See More
Firefly Neuroscience Expands Commercial Footprint 20-Fold
- Commercial Footprint Expansion: Firefly Neuroscience reported a remarkable 20-fold expansion of its commercial footprint, with partnerships reaching 99 and over 10,800 EEG/ERP brain scans completed, indicating strong growth potential in the market.
- Clinical Assessment Surge: Year-over-year, partner sites increased by 1,880% and clinical assessments surged by 3,227%, showcasing the company's rapid development and significant market acceptance in brain scanning technologies.
- Database Growth: Firefly's proprietary database now contains over 191,000 EEG/ERP brain scans, making it the largest known standardized EEG/ERP repository, which lays a solid foundation for future research and commercial applications.
- Stock Performance: Despite a 63.40% decline in share price over the past 12 months, the stock is currently trading 103.6% above its 20-day simple moving average, indicating a strong short-term rebound; however, the RSI suggests overbought conditions, warranting caution for investors.
See More
GAD Therapies Market Expected to Reach $4.26B by 2033 Amid Rising Demand
- Market Growth Potential: The global market for Generalized Anxiety Disorder (GAD) treatments is projected to grow from $1.8 billion in 2023 to $4.26 billion by 2033, reflecting a robust annual growth rate of approximately 9%, driven by increasing awareness of mental health and demand for innovative solutions.
- Diverse Treatment Options: In addition to traditional anti-anxiety and antidepressant medications, the rise of cognitive-behavioral therapy and digital mental health tools has enhanced accessibility and effectiveness, allowing patients to manage symptoms in more flexible ways.
- Helus Pharma Drug Development: Helus Pharma announced positive topline results from its Phase 2 signal detection study for HLP004, indicating significant potential for this treatment to benefit adults with moderate-to-severe GAD who have not responded to existing therapies, thus offering new hope for underserved patients.
- Investment Outlook: As mental health care becomes increasingly integrated into mainstream healthcare systems, the broader anxiety treatment market is expected to exceed $12 billion in the next decade, with ongoing investments from companies and investors likely to drive long-term growth in this sector.
See More
GAD Therapies Market Expected to Reach $4.26B by 2033 Amid Rising Demand
- Market Growth Potential: The global market for generalized anxiety disorder (GAD) treatments is projected to grow from $1.8 billion in 2023 to $4.26 billion by 2033, reflecting a 9% annual growth rate driven by increasing awareness of mental health and demand for innovative solutions.
- Therapeutic Innovation: Helus Pharma's HLP004 demonstrated significant efficacy in a Phase 2 clinical trial for moderate-to-severe GAD patients, achieving an average reduction of 10.4 points in the Hamilton Anxiety Rating Scale (p<0.0001) within six weeks, offering new hope for patients who have not responded to existing treatments.
- Positive Patient Response: At six months, 67% of participants showed treatment response and 39% achieved remission, indicating that HLP004 provides durable effects and could potentially transform the treatment landscape for GAD.
- Optimistic Industry Outlook: The rise of digital mental health tools and telehealth has significantly improved treatment accessibility, and investments by Helus Pharma and other companies in mental health solutions are expected to drive continued market growth to meet the increasing patient demand.
See More
Firefly Neuroscience Shares Surge Amid Major Growth in EEG/ERP Scans
- Expanded Commercial Footprint: Firefly reported a remarkable 20-fold expansion of its commercial footprint and a 33-fold increase in EEG/ERP brain scan volumes, indicating strong growth potential in the market.
- Partnership Growth: By the end of 2025, Firefly established partnerships with 99 commercial users, completing over 10,800 EEG/ERP brain scans, reflecting year-over-year increases of 1,880% in partner sites and 3,227% in clinical assessments, showcasing its growing influence in the industry.
- Data Storage Advantage: Firefly's proprietary database now consists of over 191,000 EEG/ERP brain scans, making it the largest known standardized EEG/ERP repository, which will enhance its capabilities in AI-driven biomarker discovery.
- Technological Innovation Outlook: CEO Greg Lipschitz stated that with an exponentially growing foundation of clean data and NVIDIA L40S GPU acceleration, Firefly is poised to achieve new breakthroughs in cognitive brain biomarker discovery, advancing its goal of building the world's first EEG/ERP-based foundation model of the human brain.
See More
Firefly Neuroscience Reports Major Operational Surge
- Commercial Footprint Expansion: Firefly Neuroscience has achieved over a 20-fold increase in its commercial footprint over the past year, indicating a significant enhancement in market penetration that is expected to drive future revenue growth.
- EEG Scan Volume Surge: The company reported a 33-fold increase in EEG/ERP brain scan volumes, reaching over 10,800 scans, reflecting strong demand and market recognition in the neuroscience field, which may attract more investor interest.
- Partnership Network Growth: Firefly now partners with 99 commercial sites, aiming to complete over 10,800 brain scans by the end of 2025, a collaborative model that will enhance its market competitiveness and brand influence.
- Positive Market Reaction: Following the operational update, Firefly Neuroscience's stock surged over 45% in Wednesday's premarket trading, demonstrating strong market confidence in its growth potential and positive investor sentiment.
See More
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Firefly Neuroscience, Inc. (NASDAQ: AIFF)
Investigation Announcement: Purcell & Lefkowitz LLP is investigating Firefly Neuroscience, Inc. to determine if its directors breached fiduciary duties related to recent corporate actions.
Shareholder Rights: Shareholders of Firefly Neuroscience are encouraged to seek information about their rights and options through the law firm, which offers consultations at no cost.
See More
